Purpose: Evaluate the efficacy of prophylactic Emicizumab administered on a scheduled basis to prevent bleeds in patients with acquired hemophilia A (AHA).
Thank you for your interest, but this study is recruiting by invitation only.
North Carolina (Statewide)
Patrick Ellsworth
Medicine-Hematology
Clinical or Medical
Interventional
Rare Diseases
23-1907
Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.
Questions?
